

WOUND HEALING ACTIVITY OF ETHANOL LEAF EXTRACT OF *ERYTHRINA SENEGALENSIS*

Ilodigwe, E. E.¹, Okonkwo, B. E.², Agbata C. A.³, Ajaghaku, D. L.⁴, and Eze, P. M.^{5*}

¹Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-Nigeria.

²Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-Nigeria.

³Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-Nigeria.

⁴Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-Nigeria.

⁵Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-Nigeria.

ABSTRACT

Aim: This study investigates the wound healing activity of ethanol leaf extract of *Erythrina senegalensis* using excision wound model on albino rats.

Methodology: Several herbal extract formulations were prepared with Petroleum Jelly ointment base. Cicatrin[®] powder (neomycin-bacitracin) was used as the positive control. The various ointment formulations were applied topically on the wounds daily for 21 days. Daily wound contraction and epithelialisation times were recorded for each group. The antibacterial activity of the extract was also evaluated against some bacteria species implicated in wound infections. The following test organisms were used: *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *klebsiella pneumoniae* and *Escherichia coli*.

Results: The Phytochemical analysis revealed that alkaloids were abundant in the extract. The herbal ointment at various concentrations showed significant ($P < .05$) increase in percentage wound contraction on day 9 – 21 compared with the control group that received only the ointment base. The contraction produced by 40% w/w of the extract was similar to that of Cicatrin[®] powder on day 6 – 21. The results also revealed significant ($P < .05$) reduction in epithelialisation time exhibited by the extract treated animals compared to those of the control group. The result of antimicrobial studies showed that the extract inhibited the test organisms at concentrations ranging from 200 to 12.5 mg/mL. The Minimum Inhibitory Concentrations (MICs) of the extract on the test isolates was recorded at 25mg/mL for both *S. aureus* and *E. coli*, and 6.25mg/ml for *K. pneumoniae*. *P. aeruginosa* showed no susceptibility to both the extract and the control drug at the concentrations evaluated.

Conclusion: The marked reduction of wound size and epithelialisation time by the extract is an indication of its wound healing potentials. Also, the antibacterial activity of this plant against bacterial species implicated in wound infections may contribute to the enhanced wound healing activity.

Keywords: *Erythrina senegalensis*, wound healing, antibacterial activity, epithelialisation, wound contraction.

*Tel.: +2348063809147

E-mail address: ezep2004@hotmail.com

46 INTRODUCTION

47 Wounds arise due to physical, chemical, immunological or microbial insult to the tissue [1]. The healing
48 process is usually complex, dynamic and varies among different tissue types. However, homeostasis,
49 inflammatory reaction, proliferation and remodelling are the common similarities shared in wound healing
50 processes [2]. These healing processes are geared towards restoration of integrity of the damaged tissue
51 [3]. Traditionally, wounds have been treated mostly topically with different medicinal plants or with their
52 extract solely or in combination with some other plant parts. Approximately, one-third of all traditional
53 medicines in use are for the treatment of wounds and skin disorders compared to only 1-3 % of modern
54 drugs [4].

55 Several researches have been carried out in the area of wound treatment and management especially
56 through medicinal plants. Wound healing activities of some plants have been reported, these include:
57 *Alternanthera sessilis* [5], *Lycopodium serratum* [6], *Morinda citrifolia* [7], *Sesamum indicum* [8],
58 *Napoleona imperialis* [9], *Lawsonia alba* [10].

59 *Erythrina senegalensis* is commonly found in Mali, Senegal and Nigeria. It is mainly grown in West Africa
60 as an ornamental plant [11]. The leaves are used to treat malaria, gastrointestinal disorders, fever,
61 diarrhea, jaundice and pain [12]. The stem barks have been shown to possess antimicrobial activities [13]
62 and also inhibits HIV-1 protease [14]. The Hepatoprotective activities of the stem bark have also been
63 documented [15]. The bark and root decoction is used for stomach disorder and wounds [11]. In
64 Cameroon and Nigeria, decoctions made from different parts of the plant are taken orally or in body baths
65 to treat malaria, fever, cough, snake bites, inflammation and prostate [12]. In Cameroon also, the stem
66 bark is used to treat liver disorders [16]. Prynflavonoids; 8-prenylleutone; auriculatin; erysengalensin O,
67 D and N; derrone; alpinumisoflavone; and 6, 8-diprenylgenisten have all been isolated from *E.*
68 *senegalensis* and have demonstrated antimicrobial and pharmacological activities [17].

69 The leaf of *E. senegalensis* is very popular in wound management in South Eastern Nigeria because it
70 offers inexpensive, readily available and effective approach to treatment of wounds, yet scientific
71 validation of this pharmacological activity has not been done. This study evaluates the wound healing
72 activity of ethanol leaf extract of *E. senegalensis* using Swiss albino rats.

73

74 MATERIALS AND METHODS

75 MATERIALS

76

77 Plant Material

78 The fresh leaves of *E. senegalensis* were collected in May, 2013 from young matured plants in Agulu,
79 Anambra State, Nigeria and was identified and authenticated by a taxonomist, Mr. Paulinus Ugwuozor, of
80 the Department of Botany, Nnamdi Azikiwe University, Awka-Nigeria. Plant authentication voucher
81 specimen number: BDCP 709. The leaves were air dried under room temperature for seven days and
82 pulverized.

83

84 Animals

85 Thirty (30) healthy and wound-free four (4) months old Swiss albino rats of both sexes, weighing 200-
86 230g, were obtained from animal house of the Department of Pharmacology & Toxicology, Faculty of
87 Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-Nigeria. The animals were allowed free
88 access to food and water *ad libitum* and were placed under standard Laboratory animal house condition.

89

90 Test Organisms

91 Pure cultures of *Escherichia coli*, *Staphylococcus aureus* and *Pseudomonas aeruginosa*, and *Klebsiella*
92 *pneumoniae* obtained from the Department of Pharmaceutical Microbiology and Biotechnology, Faculty of
93 Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka-Nigeria were used in this study.

94 Culture Media and Reagents

95 Culture media used were Nutrient Agar, Nutrient Broth and Mueller-Hinton Agar (Oxoid Limited, England).
96 Reagents used include McFarland 0.5 turbidity standard (prepared from barium chloride sulfuric acid and
97 water), Ethanol (SIGMA-ALDRICH Inc., Germany), sodium chloride (BDH Chemicals, England), Cicatrin®
98 (neomycin-bacitracin), distilled water, dimethyl sulfoxide (DMSO), etc.

99 METHODS

100 **Plant Extraction**

101 The dried powdered plant material weighing 555 g was cold macerated using 2 L of 70% v/v ethanol for
102 48 hours with intermittent agitation. The extract was filtered using Whatman No.1 filter paper, and the
103 filtrates obtained were concentrated to dryness at 40°C in vacuum using rotary evaporator.

104 **Phytochemical Test**

105 The qualitative phytochemical analysis of *Erythrina senegalensis* extracts was carried out using standard
106 protocols [18].

107

108 **Antimicrobial Activity**

109 The antibacterial activity of the ethanol extract of *E. senegalensis* was evaluated against bacteria species
110 implicated in wound infections. The following test organisms were used: *Staphylococcus aureus*,
111 *Pseudomonas aeruginosa*, *klebsiella pneumoniae* and *Escherichia coli*. Preliminary antibacterial
112 screening of the extract on test organisms was carried out by the Agar well diffusion method and the
113 Minimum Inhibitory Concentrations (MICs) were determined by the Agar dilution method.

114 **Primary Screening of Extracts for Antibacterial Activity**

115 The antibacterial activity of the extract was determined by the agar well diffusion method. Dilutions of
116 100.00, 50.00, 25.00, 12.50, 6.25 and 3.13 mg/ml were prepared in a 2-fold serial dilution from a stock
117 solution of 200mg/mL. Twenty (20) mL of molten MH agar was poured into sterile Petri dishes (90 mm)
118 and allowed to set. Standardized concentrations (McFarland 0.5) of overnight cultures of test isolates
119 were swabbed aseptically on the agar plates and holes of 6 mm diameter bored using sterile metal cork-
120 borer. 20µl of the various dilutions of each extract and control were put in each hole under aseptic
121 condition, kept at room temperature for 1 hour to allow the agents to diffuse into the agar medium and
122 incubated accordingly. Cicatrin® (25µg/mL) was used as positive control, while DMSO was used as the
123 negative control. The plates were then incubated at 37°C for 24 hours and the inhibition zones diameters
124 (IZDs) were measured and recorded. The size of the cork borer (6mm) was deducted from the values
125 recorded for the IZDs to get the actual diameter. This procedure was conducted in duplicate and the
126 mean IZDs calculated and recorded.

127

128 **Determination of Minimum Inhibitory Concentration (MIC) of the Extracts on Test Isolates**

129 Minimum inhibitory concentration (MIC) is defined as the lowest concentration of the antimicrobial agent
130 that inhibits the bacterial growth. The MICs of the plant extract on the test isolates were determined by the
131 Agar dilution method. A stock solution (1000mg/ml) of the plant extract was diluted in a 2-fold serial
132 dilution to obtain the following concentrations: 500.00, 250.00, 125.00, 62.50, and 31.25 mg/mL. Agar
133 plates were prepared by pouring 19mL of MH agar into sterile Petri plates containing 1mL of the various
134 dilutions of the extract to obtain final plate concentrations of 25.00, 12.50, 6.25, 3.13 and 1.56 mg/mL.
135 The test isolates were grown for 18 hours in Nutrient broth and culture suspensions adjusted to
136 McFarland 0.5 were streaked onto the surface of the agar plates containing dilutions of the extract. Plates
137 were incubated at 37°C for 24 hours, after which all plates were observed for growth. The minimum
138 concentration of the extracts completely inhibiting the growth of each organism was taken as the MIC.
139

140 **Formulation of Herbal Ointment**

141 The herbal extract formulation was prepared in the form of a simple ointment for topical application. The
142 ointment base (10 g Petroleum jelly B.P) was used, and 1.0, 2.0 and 4.0 g of the extract were
143 incorporated into the base using the trituration method of preparing medicated ointments. The blank
144 control ointment was prepared with only the ointment base without the extract. For each batch, 10 g of
145 blank petroleum jelly B.P. was weighed and melted in a water bath at 70°C. The required quantities of the
146 extract was weighed, added to the molten ointment base at 40°C, mixed and swirled gently and
147 continuously until a homogenous dispersion was obtained.
148

149 **Wound Induction and Treatment Using Excision Wound Model**

150 Thirty (30) Swiss albino rats were randomly divided into 5 groups of six animals each. They were
151 anesthetized with chloroform by open mask method and excision wounds inflicted [19]. The thickness of
152 the excision wound of circular area was 177mm² and 2 mm depth created along the *latissimus dorsi*

153 (dorsal thoracic region). Haemostasis was achieved by blotting the wound with cotton swab soaked in
 154 normal saline. The wounds on each animal were treated topically daily with the prepared formulations,
 155 vehicle (Petroleum jelly B.P) and Cicatrin® powder, by applying appropriate quantity of these drugs that
 156 sufficiently covers the wound area.

157
 158 The wound area was measured every 3 days and the percentage wound contraction estimated, until
 159 complete epithelialization occurred. The wound contraction was calculated as; % reduction in wound
 160 area with respect to initial wound area.

161
$$\% \text{ contraction} = (W_{AO} - W_{AT}) \times 100$$

162
$$W_{AO} = \% \text{ wound contraction on day 1}$$

163
$$W_{AT} = \% \text{ wound contraction on day T (i.e. day 2-20)}$$

164

165 **STATISTICAL ANALYSES**

166 Results were expressed as mean ± standard error of mean (SEM). Data obtained from the percentage
 167 wound contraction were subjected to the one way ANOVA using SPSS 17.0 and Student t-test. (P<.05)
 168 was considered to be significant.

169

170 **RESULTS AND DISCUSSION**

171 **Table 1: Phytochemical Analysis of *E. senegalensis***

Phytoconstituents	Occurrence
Alkaloids	+++
Carbohydrates	+
Proteins	-
Saponins	-
Tannins	+
Flavonoids	-
Glycosides	++

172 + = present in trace amount, ++ = present in appreciable amount

173 +++ = Abundant, - = Absent

174

175

176 **Table 2: Inhibition Zone Diameters (mm) of *E. senegalensis* against Test Bacteria**

Test Isolates	Concentration (mg/mL)								Controls	
	200.00	100.00	50.00	25.00	12.50	6.25	3.13	Positive	Negative	
								Cicatrin® (25mg/ml)	DMSO	
<i>E. coli</i>	5±0.5	4±0.5	2±0.0	0±0.0	0±0.0	0±0.0	0±0.0	7±0.0	0±0.0	
<i>S. aureus</i>	6±0.0	4±0.0	2±0.0	0±0.0	0±0.0	0±0.0	0±0.0	5±0.5	0±0.0	
<i>P. aeruginosa</i>	0±0.0	0±0.0	0±0.0	0±0.0	0±0.0	0±0.0	0±0.0	0±0.0	0±0.0	
<i>K. pneumoniae</i>	8±0.0	6±0.0	4±0.0	3±0.5	2±0.0	0±0.0	0±0.0	8±0.0	0±0.0	

177

178

179 **Table 3: MICs of *E. senegalensis* Against Test Isolates**

Test Organisms	MICs (mg/mL)	
	<i>E. senegalensis</i>	Cicatin®
<i>E. coli</i>	25.00	3.13
<i>S. aureus</i>	25.00	3.13
<i>P. aeruginosa</i>	-	50.00
<i>K. pneumoniae</i>	6.25	1.56

180

181

182

183 **Table 4: Percentage Wound Contraction of Ethanol Extract of *Erythrina senegalensis***

Treatment Groups	% Wound Contraction ± SEM						
	Day 3	Day 6	Day 9	Day 12	Day 15	Day 18	Day 21
10% w/w Extract Ointment	22.6±4.1A	49.4± 6.7A	70.4±3.7B*	77.4±1.8 AB	87.0±3.4A	96.0± 0.5B*	99.6±0.4B*
20% w/w Extract Ointment	21.8±3.4A	50.8±4.4A	70.4± 4.1B*	81.4±2.8B*	94.20±0.73*	98.6±6.5 C*	100.0±0.0B*
40%w/w Extract Ointment	19.0±2.7A	57.2±3.3AB*	73.2±3.0B*	85.4±2.1B*	94.8±1.5B*	99.8±0.20C*	100.0±0.0B*
Blank Ointment (Negative control)	21.4±3.6A	41.8±5.3A	55.2±3.8A	70.4±3.7A*	83.2±3.0A	92.6±1.0A	97.2±0.4A

184 Number per group = 5

185 The mean ± SD in the same column for the same category of percentage wound contraction followed by
186 same letter do not differ significantly at P < 0.05 (student Newman Keuls test).

187 * P<0.05 compared with negative control.

188

189

190

191

192 **Table 5: Epithelialisation Time of Different Formulated Ointments of *E. senegalensis***

Treatment Groups	Mean Epithelialization time (days)±SD
10% w/w Extract Ointment	16.0±1.0*
20%w/w Extract Ointment	15.6±1.1*
40% w/w Extract Ointment	14.8±0.8*
Blank Ointment (Negative control)	22.6±1.5
Cicatin® (Standard)	14.4±0.5*

193 * P<.05 compared with negative control.

194

195 The Phytochemical analysis revealed that alkaloids were abundant in the extract (Table 1). Alkaloids
196 have been documented by many studies to possess wound healing activity [20,21]. The abundance of
197 this phytochemical may have contributed to the wound healing activity exhibited by the extract.198 Wound healing has been documented to be delayed or impaired by both systemic and local factors [22].
199 One of the important local factors that may delay or prevent speedy resolution of wound is bacterial
200 infections. It usually prolongs the inflammatory phase of wound healing [23]. Also wounds are known to
201 be easy portal for infections as they provide suitable medium for the proliferation of microbial organisms
202 [24]. The result of antimicrobial studies showed that the extract inhibited the test organisms at
203 concentrations ranging from 12.5 to 200 mg/ml (Table 2), although the positive control drug, Cicatin®
204 (neomycin-bacitracin) recorded higher activities at a concentration of 25 mg/ml. Table 3 shows the MICs
205 of both the extract and the control drug on the test isolates. The MICs of the extract was recorded at 25
206 mg/ml for both *S. aureus* and *E. coli*, and 6.25mg/ml for *K. pneumoniae*. *P. aeruginosa* showed no
207 susceptibility to both the extract and the control drug at the concentrations evaluated. This may be due to

208 the intrinsically resistant nature of the organism. *P. aeruginosa*, *S. aureus*, *E. coli* and *K. pneumoniae* are
209 common micro-organisms seen in infected wounds [25,26]. The antibacterial activity of this plant against
210 these bacterial species implicated in wound infections may have contributed to its enhanced wound
211 healing activity.

212 Wound contraction is a ubiquitous feature of excision wounds and together with new extra cellular matrix
213 formation and epidermal regeneration, affects full wound closure [27]. The extract at various
214 concentrations showed significant ($P<.05$) increase in percentage wound contraction on days 9 – 21
215 compared with the control group that received only the ointment base (Table 4). The contraction
216 produced by 40% w/w of the extract was similar to that of Cicatrin[®] powder on days 6 – 21. The process
217 of wound contraction have been documented as useful mechanism for rapid minimization of exposure of
218 underlying tissue to hazardous external environmental factors that may delay the healing process [28].
219 The markedly reduction of wound size by the extract is an indication of its wound healing potentials.

220 Following excision wounds, reconstruction of injured epithelium is crucial for re-establishment of the
221 barrier function of the skin [29]. The significant ($P<.05$) reduction in epithelialisation time compared with
222 the control (Table 5) exhibited by the extract treated animals is another indication that the extract
223 accelerated the complete wound healing processes.

224

225 **CONCLUSION**

226 The results of this study justify the traditional use of this plant in the management of superficial wounds.

227

228 **COMPETING INTERESTS**

229 The authors declare no competing of interests.

230

231 **ETHICAL APPROVAL**

232 All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised
233 1985) and all experiments have been examined and approved by the appropriate ethics committee.

234 Ethical committee approval number: EC/NAU/PHARM/013/15.

235

236

237

238 **REFERENCES**

239 1. Rajinder PS, Verma PK, Pankaj NK. Medicinal plants and their role in wound healing. *Vetscan*.
240 2008;3(1):1-7.

241

242 2. LiJuan GU, Eunkyong MO, Zhittong Yang, ZheMing F, Baishen S, Chun YW, XueMei Z, JianFeng
243 B, Changkeun S. Effects of red deer antlers on cutaneous wound healing in full thickness rat
244 models. *Asian-Aust. J. Anim. Sci.* 2008; 21(2):277-290.

245

246 3. Barua CC, Talukdar A, Begum SA, Sarma DK, Fathak DC, Barua AG, Bora RS. Wound healing
247 activities of methanolic extract of leaves of *Alternanthera brasiliana* Kuntz using in vivo and invitro
248 models. *Ind. Exp. Biol.* 2009; 47:1001-1005.

249

250 4. Mantle D, Gok MA, Lennard TWJ. Adverse and beneficial effect of plant extracts on skin and skin
251 disorders: Adverse drug reaction. *Toxicol Rev.* 2001; 20(2):89-103.

252

253 5. Jalalpure SS, Agrawal N, Patil MB, Chimkode R, Tripathi A. Antimicrobial and wound healing
254 activities of leaves of *Alternanthera sessilis*. *Int. J. Green Pharm.* 2008; 2:141-144.

255

256 6. Manjunatha BK, Krishna V, Vidya SM, Mankani KL, Manohara YN. Wound healing activity of
257 *Lycopodium serratum*. *Ind. J. Pharm. Sci.* 2007; 69:283-287.

258

259 7. Nayak BS, Sandiford S, Maxwell A. Evaluation of the wound-healing activity of ethanolic extract
260 of *Morinda citrifolia* leaf. Evidence-based complementary and alternative medicine. 2007; 7:1093-
261 1095.

262

- 263 8. Dhupal SV, Kulkarni SR. Antibacterial and wound healing activity of roots of *Sesamum indicum*.
264 Indian Drugs. 2007; 44:937-944.
265
- 266 9. Esimone CO, Ibezim EC, Chah KF. The wound healing effect of herbal ointments formulated with
267 *Napoleona imperialis*. J. Pharm. Allied Sci. 2005; 3:294-299.
268
- 269 10. Mandawade SD, Patil KS. Wound healing potential of some active principles of *Lawsonia alba*
270 leaves. Ind. J. Pharm. Sci. 2003; 65:390-394.
271
- 272 11. Tepongning RN, Yerbanga SR, Dori GU, Lucantoni L, Lupidi G, Habluetzel A. In vivo efficacy and
273 toxicity studies on *Erythrina senegalensis* and *Khaya ivorensis* used as herbal remedies for
274 malaria prevention in Cameroon. European J of Medicinal Plants. 2013; 3(3):454-464.
275
- 276 12. Togola A, Astarheim I, Theis A, Diallo DH, Paulsen BS. Ethnopharmacological uses of *Erythrina*
277 *senegalensis*: a comparison of three areas in Mali, and a link between traditional knowledge and
278 modern biological science. Journal of ethnobiology and ethnomedicine. 2008; 4:6.
279
- 280 13. Doughari H. Evaluation of antimicrobial potentials of stem bark extract of *Erythrina senegalensis*
281 DC. Afr. J. Microbiol. Res. 2010; 4(17):1836-1841.
282
- 283 14. Lee J, Oh WK, Ahn JS, Kim YH, Mbafor JT, Wandji J and Fomun ZT. Prenylisoflavonoids from
284 *Erythrina senegalensis* as novel HIV-1 protease inhibitors. Planta Med. 2009; 75:268-270.
285
- 286 15. Donfack JH, Njayou FN, Ngameni B, Tchana A, Chuisseu PD, Finzi PV. In vitro Hepatoprotective
287 and antioxidant activities of diprenylated isoflavonoids from *Erythrina senegalensis* (fabaceae).
288 Asian Journal of Traditional Medicines. 2008; 3(5):172-178.
289
- 290 16. Atsamo AD, Nguelefack TB, Datte JY, Kamanyi A. Acute and suchronic oral toxicity assessment
291 of the aqueous extract from the stem bark of *Erythrina Senegalensis* DC (fabaceae) in rodents. J
292 Ethnopharmacol. 2011; 134(3):697-702.
293
- 294 17. Otimenym SO, Uzochukwu DC. Spasmolytic and Anti-Diarrhea effect of the bark of *Erythrina*
295 *senegalensis* and root of *Kigalia Africana*. Asian Journal of Pharmaceutical and Clinical
296 Research. 2013; 3(4):11-14.
297
- 298 18. Trease GE, Evans WC. Textbook of pharmacognosy 12th ed. Bailliere Tindal, London. 1983;
299 343-383.
300
- 301 19. Thakur R, Jain N, Pathak R, Sandhu S. Practice in wound Healing of studies of plants. Evidence-
302 based complementary and alternative medicine. 2011; 17.
303
- 304 20. Zyuz'kov GN, Krapivin AV, Nesterova YU, Povetieva TN, Zhdanov VV, Suslov NI, *et al*.
305 Mechanisms of regenerative effects of Baikal aconite diterpene alkaloids. Bulletin of Experimental
306 Biology and Medicine. 2012; 153(6):847-851.
307
- 308 21. Nagappan T, Segaran TC, Wahid MEA, Ramasamy P, Vairappan CS. Efficiency of carbazole
309 alkaloids, essential oil and extract of *murrayan koenigii* in enhancing subcutaneous wound
310 healing in rats. Molecules. 2012; 17:14449-14463.
311
- 312 22. Molan H. Textbook of Pathology. 5th ed. Japee Brothers Medical Publisher, India; 2005.
313
- 314 23. Menke NB, Witten DG, Bonchev DG, Diegelmann RF. Impaired wound healing. Clinical
315 Dermatological Journal. 2002; 25:19-25.
316
- 317 24. Odimegwu D, Ibezim E., Esimone C, Nworu C, Okoye F. Wound healing and antibacterial
318 activities of the extract of *Dissotis theifolia* stem formulated in a simple ointment base: Journal of
319 Medicinal Plants Research. 2008; 2:11-16.
320
- 321 25. Kumar V, Abbas KA, Fausto N, and Mitchell RN. Robbins Basic Pathology. 8th ed. Saunders,
322 Pennsylvannia; 2007:68-78.

323
324
325
326
327
328
329
330
331
332
333
334
335

26. Khoo Y, Halim AS, Singh KB, Mohamed N. Wound contraction effects and antimicrobial properties of Tualang honey on full-thickness burn wounds in rats in comparison to hydrofibre. *BMC Complementary and Alternative Medicine*. 2010; 10(48):1-8.

27. Olsen L, Sherratt JA, Maini PK. A mechanochemical model for adult dermal wound contraction. *Journal of Biological System*. 1995; 3(4):1021-1031.

28. Fred V, Olmer VR. A mathematical model for wound contraction and angiogenesis, tissue regeneration- from basic biology to clinical application. Jamie D, editor. In *Tech*; 2012.

29. Monaco JL, Lawrence WT. Acute wound healing: An overview. *Clin Plastic Surg* 2003; 30:1-12.